Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.
Caswell-Jin JL, Somerfield MR, Khan MA, Kimmick GG, Gupta S, Kenan K, Peswani N, Hershman DL, Ernst BJ, Harvey BE, Krings G, McAndrew NP, Riaz IB, Vaz-Luis I, Villarreal-Garza C, Oberoi JK, Sadiq MH, He H, Chitale R, Hassett MJ
Cyclin E-CDK2 regulates cancer cell transcriptional program and response to immunotherapy through BRD4.
Chu C, Zheng S, Mitchell N, Li Z, Zhang X, Wu X, Zhang T, Dang F, Michowski W, Kolodziejczyk A, Xu ML, Kotowski KW, Yang Z, Martinez-Alonso D, Paulo J, Sheng J, Kirby JA, Groezinger F, Zhou Y, He M, Ito Y, Gulvady AC, Cole MI, Foidart P, Nishida J, Ning X, Sharma S, Suski JM, Fassl A, Zhou Y, Geng Y, Wei W, Gygi SP, Polyak K, Wucherpfennig KW, Sicinski P
Progression-Free Survival in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review: A Systematic Review and Meta-Analysis.
Ravani LV, Bagheri Z, Kalinsky K, Burstein HJ, Bardia A, Mouabbi JA, O'Regan R, Wander SA
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.
Tarantino P, Li T, Ogayo ER, Rahman T, DiLullo MK, Patel A, El-Refai S, Abbott C, Li B, Boyle SM, Chen RO, Desai NV, Spring LM, Tung NM, Sinclair N, Faggen M, Constantine M, King TA, Krop IE, Tayob N, Mittendorf EA, Tolaney SM, Winer EP, Parsons HA, Waks AG
Proteolysis activity mapping and substrate discovery platform for identifying tumor-activated biosensors.
Algov I, Van Heest A, Hopton M, Liang F, Holmes A, Hao L, Zhou X
Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2- MBC patients living in disadvantaged neighborhoods.
Lynce F, Liu X, Li B, McRoy L, Chen C, Liu R, Rugo HS
Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial.
Garrido-Castro AC, Graham N, Li KX, Bi L, Crowdis J, Bi K, Park J, Pastorello R, Li Y, Gupta H, Kuntz T, Petry R, Pasquina LW, Patel A, Lange P, DiLullo M, Attaya V, Frey AM, Childress MA, Wesolowski R, Sinclair N, Sinclair S, Lo S, Tung N, Faggen M, Kaufman PA, Block CC, Walsh J, Toke M, Chen W, Wucherpfennig KW, Tian Y, Williams AJ, Mukhopadhyay S, Dasgupta T, Schnitt S, Cherniack AD, Barroso R, Ligibel J, Lin NU, Mittendorf EA, Tayob N, Van Allen E, Tolaney SM
Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer.
Cheng X, Zhang Y, Qian C, Holdridge E, Ananda G, Jiang T, Ni J, Xie S, Gu H, Ji R, Ivanova EV, Nucci MR, Wang Z, Chen K, Kochupurakkal B, Freeman GJ, Shapiro GI, Liu J, Konstantinopoulos PA, Matulonis U, Zhao JJ
Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients.
Valenza C, Zheng Y, Milano M, Berton Giachetti PPM, Trapani D, Giordano E, Guidi L, Boldrini L, Castellano G, Katrini J, Malagutti B, Antonarelli G, Etessami JD, Bianco N, Conforti F, Kirkner GJ, Sangalli C, Dibble KE, Fusco N, Colleoni M, Regan MM, Munzone E, Curigliano G, Partridge AH
Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial.
Pagani O, Niman SM, Ruggeri M, Peccatori FA, Azim HA, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Warner E, Amant F, Mailliez A, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Ferreiro T, Ribi K, Ruddy KJ, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Partridge AH, ,
Healthy Lifestyle Advice and Practice Among Cancer Survivors in the US.
Cao C, Schmitz KH, Giovannucci EL, Lee IM, Partridge AH, Ligibel JA
Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer.
Leone JP, Leone J, De Placido P, Nakhlis F, Schlam I, Hirko KA, Hazra A, Troll E, Bellon JR, Vallejo CT, Lin NU, Tolaney SM, Lynce F
